NASDAQ:GNPX Genprex (GNPX) Stock Price, News & Analysis $2.29 +0.20 (+9.57%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$2.23 -0.06 (-2.62%) As of 04:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Genprex Stock (NASDAQ:GNPX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genprex alerts:Sign Up Key Stats Today's Range$2.11▼$2.3850-Day Range$1.81▼$3.7552-Week Range$1.71▼$110.00Volume161,045 shsAverage Volume181,855 shsMarket Capitalization$1.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Genprex, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s approach is based on delivering therapeutic genes to diseased cells using non-viral delivery systems, including lipid nanoparticles. Genprex’s lead program, REQORSA Immunogene Therapy, is designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. The company has been evaluating REQORSA in combination with established treatments for non-small cell lung cancer, including targeted and immune-based therapies. Genprex has also pursued gene therapy applications in diabetes, reflecting its broader focus on using genetic medicine to address diseases with significant unmet medical needs. Based in Austin, Texas, Genprex has historically focused its development efforts on the U.S. biotechnology and pharmaceutical markets. Its programs remain investigational and are subject to clinical testing and regulatory review; the company’s products are not approved for commercial use unless and until authorization is obtained from the relevant regulatory authorities.AI Generated. May Contain Errors. Read More Genprex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreGNPX MarketRank™: 0.532948280385 of 5 starsGenprex scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGenprex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGenprex has only been the subject of 1 research reports in the past 90 days.Read more about Genprex's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioGenprex has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Genprex's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.07% of the float of Genprex has been sold short.Short Interest Ratio / Days to CoverGenprex has a short interest ratio ("days to cover") of 0.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genprex has recently decreased by 1.33%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenprex does not currently pay a dividend.Dividend GrowthGenprex does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.20 News SentimentGenprex has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Genprex this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Genprex to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genprex insiders have not sold or bought any company stock.Percentage Held by Insiders0.25% of the stock of Genprex is held by insiders.Percentage Held by Institutions14.05% of the stock of Genprex is held by institutions.Read more about Genprex's insider trading history. Receive GNPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNPX Stock News HeadlinesGenprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy SymposiumNovember 11 at 7:00 AM | prnewswire.comGenprex Reports Reqorsa Translational Analysis in Lung Cancer PatientsNovember 5, 2026 | tipranks.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 12 at 1:00 AM | Weiss Ratings (Ad)Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated StressNovember 5, 2026 | prnewswire.comGenprex Identifies TROP2 Biomarker for Reqorsa Treatment ResponseNovember 4, 2026 | tipranks.comGenprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung CancerNovember 4, 2026 | prnewswire.comGenprex highlights TUSC2 gene therapy aging researchOctober 28, 2026 | tipranks.comGenprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific MeetingOctober 28, 2026 | prnewswire.comSee More Headlines GNPX Stock Analysis - Frequently Asked Questions How have GNPX shares performed this year? Genprex's stock was trading at $38.50 at the start of the year. Since then, GNPX stock has decreased by 94.1% and is now trading at $2.29. How were Genprex's earnings last quarter? Genprex (NASDAQ:GNPX) released its quarterly earnings results on Friday, August, 14th. The company reported ($9.40) earnings per share (EPS) for the quarter. When did Genprex's stock split? Genprex shares reverse split before market open on Friday, February 2nd 2024.The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Genprex IPO? Genprex (GNPX) raised $6 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 1,280,000 shares at a price of $5.00 per share. How do I buy shares of Genprex? Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genprex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genprex investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), NIO (NIO), Citius Pharmaceuticals (CTXR), Micron Technology (MU) and FuelCell Energy (FCEL). Company Calendar Last Earnings8/14/2026Today11/12/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GNPX's financial health is in the Red zone, according to TradeSmith. GNPX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GNPX CIK1595248 Webwww.genprex.com Phone(877) 774-4679FaxN/AEmployees13Year Founded2009Profitability EPS (Trailing Twelve Months)($133.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-163.12% Return on Assets-128.98% Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio6.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$53.16 per share Price / Book0.04Miscellaneous Outstanding Shares820,000Free Float818,000Market Cap$1.88 million OptionableNo Data Beta-0.95 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:GNPX) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThis 10.3% war bond closed once. It's finally open again.Todd Phillips has spent 30 years studying safe-money income. His test for real retirement income: can it promi...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
